EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) gene mutations have been identified as predictors of the effect of EGFR-tyrosine kinase inhibitors (TKIs) on EGFR mutation-positive non-small cell lung cancer (NSCLC) [1–3].